Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO Tue, Jun 30, 2020 17:45 CET. STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO.
STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, … Read more
Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd Contact Email jakob.lindberg@oncopeptides.se. Phone Number 46 7 05 69 54 71. Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015. Oncopeptides lead compound, named melflufen, is a peptidase potentiated therapy within oncology. Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases.
Om Ygalo® Jakob-Lindberg-VD-Oncopeptides-fj. Publicerat den 19 augusti, 2019 vid 1000 × 774 under Framtidens japanska ledare – i Stockholm! Kommentarer är stängda 26 maj 2020 — Vd Jakob Lindberg om Oncopeptides senaste rapport. 27 jan. 2020 — ”Det är vad vi ämnar att korrigera”, sade Oncopeptides vd Jakob Lindberg apropå varför bolaget anordnade en telefonkonferens på För ytterligare information kontakta: Jakob Lindberg, VD för Oncopeptides E-post: jakob.lindberg@oncopeptides.com Telefon: +46 (0) 8 615 20 40 Rein Piir, chef Oncopeptides vd Jakob Lindberg har köpt 45.000 aktier i bolaget för 42:46 kronor per aktie i en transaktion daterad den 24 februari. Det framgår av 16 juni 2020 — CSO Jakob Lindberg. Sector: Health care - Pharmaceuticals & Biotechnology.
2020 — Melflufen bryts enligt Oncopeptides vd Jakob Lindberg inte ned i blodplasma enligt bolagets studier. I stället tas det efter injektionen snabbt upp I enlighet med vad som meddelande i tisdagens förhandsbesked har Oncopeptides forskningschef Jakob Lindberg sålt 100.000 aktier i bolaget.
2020-08-03
På Eniro kan du hitta Stig Anders Jacobs för 7 dagar sedan — REIN PIIR, BSc Avanza Lunch presentation – Oncopeptides Investor a presenteras av vd Jakob Lindberg Forskningsbolaget Oncopeptides STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Jakob Lindberg, Med Lic Chief Scientific Officer, CSO Jakob Lindberg was appointed as CSO in 2020. In addition to being CSO of Oncopeptides, Jakob is a Venture Partner at Patricia Industries, a part of Investor AB. STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO PRESS RELEASE PR Newswire Jun. 30, 2020, 05:54 PM Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011.
Oncopeptides VD Jakob Lindberg intervjuad i DI Börsmorgon om Q1 rapporten och framtiden, 17 maj 2018.
Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd. Publicerad: 2020-06-30 (Cision) Oncopeptides AB: Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd tis, jun 30, 2020 17:45 CET Marty J Duvall ersätter Jakob Lindberg som varit vd sedan bolagets nystart 2011. We wouldn’t blame Oncopeptides AB (publ) shareholders if they were a little worried about the fact that Jakob Lindberg, the Chief Executive Officer recently netted about kr60m selling shares at an average price of kr125.That sale reduced their total holding by 47% which is hardly insignificant, but far from the worst we’ve seen. View our latest analysis for Oncopeptides “When we listed Oncopeptides on Nasdaq Stockholm, we promised to establish melflufen as an attractive treatment option for patients with multi-resistant disease. With the approval of PEPAXTO, that has finally become reality,” says Jakob Lindberg, Chief Scientific Officer at Oncopeptides. 2020-05-08 Oncopeptides styrelse har utsett Marty J Duvall till ny vd.
Jakob Lindberg assumes the role as Chief Scientific Officer, … Read more
Oncopeptides AB, a Karolinska Development AB portfolio company, today announced the appointment of Jakob Lindberg as new CEO. Mr. Lindberg holds a Med. Lic. in Molecular Immunology a MSc in pre-clinical medicine from the Karolinska Institutet in Sweden and a BA in Finance and Administration from the Stockholm University. “We are proud to bring forward the first anticancer peptide-drug conjugate approved by the FDA for multiple myeloma,” said Jakob Lindberg, Chief Scientific Officer at Oncopeptides. “PEPAXTO uses innovative technology that links a peptide carrier to a cytotoxic agent. STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive
Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO Published: Jun 30, 2020 STOCKHOLM , June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer
Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO PRESS RELEASE PR Newswire Jun. 30, 2020, 05:54 PM
STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011.
Shopify sverige klarna
In addition to being CSO of Oncopeptides, Jakob is a Venture Partner at Patricia Industries, a part of Investor AB. STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011.
I stället tas det efter injektionen snabbt upp
I enlighet med vad som meddelande i tisdagens förhandsbesked har Oncopeptides forskningschef Jakob Lindberg sålt 100.000 aktier i bolaget. Försäljningen
6 dec.
Pernilla wahlgren
View our latest analysis for Oncopeptides . The Last 12 Months Of Insider Transactions At Oncopeptides . In fact, the recent sale by Jakob Lindberg was the biggest sale of Oncopeptides shares made by an insider individual in the last twelve months, according to our records.
tisdag den 30 juni klockan 17:51. Forskningsbolaget Oncopeptidens har utsett Marty 27 jan. 2020 — Melflufen bryts enligt Oncopeptides vd Jakob Lindberg inte ned i blodplasma enligt bolagets studier. I stället tas det efter injektionen snabbt upp I enlighet med vad som meddelande i tisdagens förhandsbesked har Oncopeptides forskningschef Jakob Lindberg sålt 100.000 aktier i bolaget. Försäljningen 6 dec. 2019 — Oncopeptides vd Jakob Lindberg uppger att Glaxosmithkline försökte lämna in abstract, men blev nekade, vilket är anmärkningsvärt.
111 37. Sweden. +46.8.6152040. https://www.oncopeptides.se/. Executive Leadership. Per Wold-Olsen. Independent Chairman of the Board. Jakob Lindberg.
Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO PRESS RELEASE PR Newswire Jun. 30, 2020, 05:54 PM Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, … Read more Oncopeptides AB, a Karolinska Development AB portfolio company, today announced the appointment of Jakob Lindberg as new CEO. Mr. Lindberg holds a Med. Lic. in Molecular Immunology a MSc in pre-clinical medicine from the Karolinska Institutet in Sweden and a BA in Finance and Administration from the Stockholm University.
Jakob Lindberg assumes the role as Chief Scientific Officer, … Read more Jakob Lindberg is Chief Scientific Officer at Oncopeptides AB. See Jakob Lindberg's compensation, career history, education, & memberships. Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J STOCKHOLM - June 30, 2020 - Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. At my last company I attended several major oncology/hematology scientific meetings. I attended a couple of Oncopeptides’ data sessions. I found the data presented by Jakob Lindberg, Med Lic, Oncopeptides’ Chief Scientific Officer, compelling and I could also tell immediately how passionate he was to help patients suffering with Multiple View our latest analysis for Oncopeptides .